SGLT2 inhibitors in heart failure with reduced ejection fraction: a paradigm shift towards dual cardio-renal protection - Université de Lorraine
Article Dans Une Revue Heart Failure Clinics Année : 2022

SGLT2 inhibitors in heart failure with reduced ejection fraction: a paradigm shift towards dual cardio-renal protection

Résumé

Sodium-glucose transport inhibitors (SGLT2i) have been found to be effective in preventing heart failure in patients with diabetes or chronic kidney disease with or without cardiovascular disease. Recent evidence suggests that SGLT2i substantially improve cardiovascular and renal outcomes in patients with heart failure with reduced ejection fraction (HFrEF). In this review, we discuss the combined cardio-renal benefits of SGLT2i in patients with HFrEF. In addition, we discuss the impact of renoprotection in the midterm management of HFrEF and possible implementation strategies for initiating SGLT2i in routine care of HFrEF.
Fichier principal
Vignette du fichier
SGL2i in HFrEF_final.pdf (1.11 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03810997 , version 1 (11-10-2022)

Licence

Identifiants

Citer

Tripti Rastogi, Nicolas Girerd. SGLT2 inhibitors in heart failure with reduced ejection fraction: a paradigm shift towards dual cardio-renal protection. Heart Failure Clinics, 2022, 18 (4), pp.561-577. ⟨10.1016/j.hfc.2022.03.006⟩. ⟨hal-03810997⟩
140 Consultations
69 Téléchargements

Altmetric

Partager

More